Loading
When a treatment kills cancer cells faster than the body can clear their contents, flooding the blood with potassium, phosphate and uric acid and injuring the kidneys and heart. Risk is highest in bulky CLL and high-count AML, which is why venetoclax starts at a tiny dose and ramps up over weeks.
Hyperuricaemia, hyperkalaemia, hyperphosphataemia, hypocalcaemia, and acute kidney injury after rapid cell kill. Risk is highest with bulky CLL and high counts in AML. Venetoclax uses a 5-week ramp-up in CLL (20→400 mg) and a 3-day ramp in AML, with hydration, allopurinol or rasburicase, and monitoring; sonrotoclax uses a 4-week ramp.
Ball-and-stick model from PubChem 2D record (no 3D conformer available). PubChem record
Showing the molecule this term concerns: Venetoclax.
Shares Xanthine oxidase (XDH), Tumour lysis syndrome in lymphoma: who is at risk, and rasburicase, Burkitt lymphoma, Chronic lymphocytic leukaemia.
Shares Burkitt lymphoma, Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Mantle cell lymphoma, Chronic lymphocytic leukaemia.
Shares Burkitt lymphoma, Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Mantle cell lymphoma, Chronic lymphocytic leukaemia.
Shares Sonrotoclax, Venetoclax, Chronic lymphocytic leukaemia, Acute myeloid leukaemia.
Shares Sonrotoclax, Venetoclax, Chronic lymphocytic leukaemia, Acute myeloid leukaemia.
Shares CLL14, Chronic lymphocytic leukaemia, first treatment, Venetoclax, Chronic lymphocytic leukaemia.
Shares Sonrotoclax, Chronic lymphocytic leukaemia, first treatment, Venetoclax, Chronic lymphocytic leukaemia.
Shares Burkitt lymphoma, Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Mantle cell lymphoma, Diffuse large B-cell lymphoma.